Blog
Filter blogs by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Looking forward: The most significant 2024 US healthcare trends—Part 3 of 5
Physical- and mental-health measure declines are 2 factors likely to impact the healthcare industry as they move forward in 2024 and beyond. Not surprisingly, concerns over rising healthcare costs and how to best control them continue to dominate in significance.
-
Looking forward: The most significant 2024 US healthcare trends - Part 2 of 5
In addition to physical health indicators, mental health declines also serve as a measure of the serious health concerns to the healthcare industry in the United States. These changes likely impact drug manufacturers directly and indirectly through market needs, opportunities, and resource allocations related to the development and marketing of both existing and prospective treatments.
-
Looking forward: The most significant 2024 US healthcare trends - Part 1 of 5
2024 may well be the most challenging year yet for the US healthcare industry. Our research reveals 5 overarching trends likely to have the strongest impact on the industry and improving the health of Americans for the months and years ahead.
-
How pharma can use social determinant of health to address health equity
The majority of our disease risk is social and environmental, not genetic, meaning the social determinants of health are a key piece of the puzzle. Effectively leveraging SDoH data can help close the gap in health equity and reveal new insights to guide pharma brand growth.
-
How data intelligence tools are enhancing signal detection methods
Advancements in intelligence tools such as ICON’s Signet help overcome challenges with data volume, complexity and completeness to accurately and rapidly detect safety signals to ensure patient safety throughout the drug’s lifecycle.
-
Trialling abroad: How sponsors, ethics committees and regulators can improve patient outcomes in cross-border trials
Patients’ need for novel investigational treatments for life-impacting diseases in the absence of available treatment options drives an ongoing debate on how sponsors, ethics committees and regulatory bodies can work together to overcome both logistical and regulatory barriers.
-
Continuing the fight against AMR with new tools for diagnosis and treatment
The employment of antimicrobials to fight previously devastating microbial diseases, such as tuberculosis, meningitis and pneumonia, has been credited as being one of the most transformative medical achievements of the 20th century.
-
The impact of pediatric medical trauma in clinical trials
Up to 80% of children and their families experience pediatric medical trauma after medical interactions of significant illnesses. Read the insights shared by a panel of Pediatric Medical Trauma Working Group members to learn how patient-centric pediatric trials can help mitigate the potential for medical trauma and its life-long implications.
-
Navigating CTIS: Setting up clinical trials under EU CTR
The EU CTR Nº 536/2014 came into force on 31 January 2022, repealing the Clinical Trials Directive and improving the harmonisation of clinical trials regulation throughout the EU and European Economic Area (EEA).
-
Digital therapeutics considerations for CNS
This blog explores DTx in CNS clinical trials: regulatory landscape, data management, endpoints, payer coverage, and future trends.
-
Expanding CAR T-cell Therapy into solid tumours
In this blog, learn more about a range of approaches that researchers are taking to improve the efficacy and safety of CAR T-cell therapies in solid tumours.
-
Keeping up to date with the latest regulatory developments for decentralised clinical trials
This blog examines the crucial topic of regulating the use of DCTs, exploring what’s in place now and what sponsors need to consider as these methods continue to gain traction.
-
Realising the benefits of bringing decentralised cardiovascular trials to patients
This blog reflects on the success of the first fully decentralised cardiovascular trial during the COVID-19 pandemic and highlights key elements for future trials.
-
Highlights from the revised Medicare Drug Price Negotiation program guidance
Explore revised guidance instructions related to the Medicare Price Negotiation program in this blog.
-
CMS Medicare Part D Price Negotiations
In this blog find more about a current list of drugs likely to be selected for negotiation, with their same-in-class competitors.
-
The new EMA guideline expectations
In this blog, discover more about the new EMA guideline on computerised systems and electronic data in clinical trials.
-
Patient-centric best practices for improved diversity
In this blog, we share best practices for a more patient-centric approach to trials as discussed in our webinar to improve accessibility, inclusion and diversity.
-
Disease surveillance in low- and middle-income countries
Disease surveillance and reporting is critical to public health, enabling faster and better response to infectious disease outbreaks.
-
Best practices for KPI management in FSP partnerships
Learn more about the best practices for KPI creation and management in this blog.
-
Disease surveillance and innovative vaccines
Learn about current approaches to disease surveillance and why they are important for the advancement of vaccine development in this blog.